Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 0054-0401

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 0054-0401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hikma Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1

This is a table displaying information related to renal and hepatic impairment, population description, gender, age, and pharmacokinetics. The table includes categories for the level of impairment and the geometric mean ratio for various parameters such as Cmax and AUC. The table also provides a definition for ESRD (End Stage Renal Disease).*

FDA Label Image

Figure2

The text seems to be a table presenting the results of a study on the effect of Ketoconazole on CYP3A4. The table shows the geometric mean ratio (90% confidence interval) and the change resulting from PK for different parameters: Cmax, AuC, and T. The values depict the change relative to the reference and the results of the study indicate that the use of Ketoconazole has a statistically significant effect on the CYP3A4 which is demonstrated by the increase in the geometric mean ratio for all parameters observed.*

FDA Label Image

Figure3

This appears to be a table showing the effects of the drug Pristiq (in various doses) on the metabolism of other drugs. These effects are measured by changes in Cmax and AUC, which are indicators of drug concentration in the bloodstream. The table also shows the geometric mean ratios for these effects. The text mentions the drugs Desipramine, Midazolam, Tamoxifen, and Aripiprazole as examples.*

FDA Label Image

Figure4

FDA Label Image

Figure5

FDA Label Image

Label-50mg-30tabs.jpg (Image 01)

FDA Label Image

Image 02

Each tablet of the medication contains 76 g of desvenlaxine succiriate equivalent to 50 mg aeserlaaxine. The tablets are film-coated and designed for extended-release. Swallow the whole tablet and do not chew, crush, cut, or dissolve it. The product should be stored at 20° to 25°C. (66° to TT°F) in USP Controlled Acorn Temperature. It comes in a package of 30 tablets, and the package is a unit-of-use. The medication guide should be distributed to each patient, according to the pharmacist. The medication is distributed by Hikma Reony Pharmaceuticals USA Inc. in Berkeley Heights, NJ 07522.*

FDA Label Image

Image 03

FDA Label Image

Image 04

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.